AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8466068 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 8466068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of regular insulin (20 u)
Number of subjects: 40
Study 3082644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine, 50 mg twice a day
Number of subjects: 9
Study 3082644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin, 20 mg twice a day
Number of subjects: 9
Study 3082644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31790563 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PiB SUVR
Number of subjects: 175
Study 31790563 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PiB SUVR
Number of subjects: 175
Study 29617064 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication alone
Number of subjects: 395
Study 29617064 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication with CGT
Number of subjects: 395
Study 29617064 — intervention group
Group type: EXPERIMENTAL
Intervention: CGT
Number of subjects: 395
Study 29617064 — intervention group
Group type: EXPERIMENTAL
Intervention: CGT for SB participants
Number of subjects: 395
Study 29617064 — intervention group
Group type: EXPERIMENTAL
Intervention: Other outcomes for SB participants
Number of subjects: 395
Study 26970401 — intervention group
Group type: EXPERIMENTAL
Intervention: Certified nurse‐midwife telephone‐administered interpersonal psychotherapy (CNM‐IPT) sessions (up to eight 50-minute sessions)
Number of subjects: 61
Study 26970401 — intervention group
Group type: COMPARATOR
Intervention: Control group referred to mental health professionals
Number of subjects: 61
Study 26970401 — intervention group
Group type: EXPERIMENTAL
Intervention: CNM‐IPT
Number of subjects: 61
Study 25424297 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (25 µg) combined with hyperbaric bupivacaine 0.5% (10mg)
Number of subjects: 64
Study 25424297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (5.0 µg) combined with hyperbaric bupivacaine 0.5% (10mg)
Number of subjects: 64
Study 25424297 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Fentanyl and Sufentanil)
Number of subjects: 64
Study 21424698 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib with gemcitabine (arm B)
Number of subjects: 37
Study 21424698 — intervention group
Group type: COMPARATOR
Intervention: sorafenib alone (arm A)
Number of subjects: 37
Study 19671919 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 271
Study 17572323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 30
Study 17572323 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (REM)
Number of subjects: 30
Study 12951862 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg, twice-weekly subcutaneous injections for 4 months)
Number of subjects: 40
Study 12951862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11121908 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily (EAC)
Number of subjects: 448
Study 11121908 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice daily (OAC)
Number of subjects: 448
Study 9124240 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate
Number of subjects: 240
Study 9124240 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone
Number of subjects: 240
Study 9124240 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft acrylic
Number of subjects: 240
Study 7645790 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (Versed), 0.4 mg/kg
Number of subjects: 30
Study 7645790 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (Ketalar), 3 mg/kg
Number of subjects: 30
Study 7645790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (Sufenta), 1.5 micrograms/kg
Number of subjects: 30
Study 7645790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (Sufenta), 1.0 microgram/kg
Number of subjects: 30
Study 3099943 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir 800 mg five times daily for seven days
Number of subjects: 205
Study 31167867 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseworker-delivered multicomponent intervention (behavioural counselling, nicotine spray, referral to Quitline and primary care)
Number of subjects: 0
Study 31167867 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 30265329 — intervention group
Group type: COMPARATOR
Intervention: No biopsy and no artificial shrinkage (Clinic 1)
Number of subjects: 2129
Study 30265329 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophectoderm biopsy and vitrification of collapsed blastocyst within 30 min (Clinics 1 and 2)
Number of subjects: 2129
Study 30265329 — intervention group
Group type: EXPERIMENTAL
Intervention: No biopsy but laser-assisted artificial shrinkage (Clinic 2)
Number of subjects: 2129
Study 30265329 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor morphological quality pre-vitrification
Number of subjects: 2129
Study 30265329 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking 7 days to reach full blastulation
Number of subjects: 2129
Study 30265329 — intervention group
Group type: EXPERIMENTAL
Intervention: Average morphological quality
Number of subjects: 2129
Study 30265329 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor morphological quality
Number of subjects: 2129
Study 30265329 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of spontaneous hatching pre-vitrification
Number of subjects: 2129
Study 30265329 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor-quality blastocysts pre-vitrification
Number of subjects: 2129
Study 27460692 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Hz/high amplitude (40H)
Number of subjects: 16
Study 27460692 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Hz/low amplitude (50L)
Number of subjects: 16
Study 27460692 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Hz/high amplitude (50H)
Number of subjects: 16
Study 27460692 — intervention group
Group type: EXPERIMENTAL
Intervention: All WBV protocols
Number of subjects: 16
Study 25266182 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 102
Study 25266182 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting (ONCAB)
Number of subjects: 102
Study 25266182 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OPCAB and ONCAB
Number of subjects: 102
Study 23327023 — intervention group
Group type: EXPERIMENTAL
Intervention: Gargling with ketamine 40 mg in 30 ml saline for 60 seconds (Group K)
Number of subjects: 75
Study 23327023 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% betamethasone gel applied over endotracheal tube (Group B)
Number of subjects: 75
Study 23327023 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 75
Study 20874515 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg of H1N1 hemagglutinin vaccine
Number of subjects: 1313
Study 20874515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1313
Study 17207457 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure plus response-prevention (E/RP)
Number of subjects: 20
Study 17207457 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition (Control)
Number of subjects: 20
Study 15942235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin (2 g/day)
Number of subjects: 334
Study 15942235 — intervention group
Group type: COMPARATOR
Intervention: Pristinamycin (2 g/day)
Number of subjects: 334
Study 15942235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 334
Study 15942235 — intervention group
Group type: COMPARATOR
Intervention: Pristinamycin
Number of subjects: 334
Study 12649032 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexed to 70 degrees for 6 h post-operatively (Group 2)
Number of subjects: 60
Study 12649032 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg elevated 35 degrees at the hip with knee extended for 6 h post-operatively (Group 3)
Number of subjects: 60
Study 12649032 — intervention group
Group type: COMPARATOR
Intervention: Knee extended and level with bed (Group 1)
Number of subjects: 60
Study 10472877 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxytocin (4.5 mU/minute initially, increased by 4.5 mU/minute every 30 minutes) for induction
Number of subjects: 1307
Study 10472877 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oxytocin (1.5 mU/minute initially, increased by 1.5 mU/minute every 30 minutes) for induction
Number of subjects: 1307
Study 10472877 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxytocin for augmentation
Number of subjects: 1307
Study 10472877 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oxytocin for augmentation
Number of subjects: 1307
Study 10472877 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxytocin for induction in nulliparous women
Number of subjects: 1307
Study 10472877 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oxytocin for induction in nulliparous women
Number of subjects: 1307
Study 10472877 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxytocin for induction in nulliparous women (cephalopelvic disproportion)
Number of subjects: 1307
Study 10472877 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oxytocin for induction in nulliparous women (cephalopelvic disproportion)
Number of subjects: 1307
Study 8912741 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with COPD
Number of subjects: 27
Study 8912741 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 27
Study 1862062 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative education alone
Number of subjects: 0
Study 1862062 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance skill training alone
Number of subjects: 0
Study 1862062 — intervention group
Group type: EXPERIMENTAL
Intervention: Both resistance skill training and normative education
Number of subjects: 0
Study 1862062 — intervention group
Group type: COMPARATOR
Intervention: Neither of the experimental curricula (placebo comparison)
Number of subjects: 0
Study 6627821 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (50 to 800 mg)
Number of subjects: 6
Study 6627821 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Amphetamine sulfate (25 mg)
Number of subjects: 6
Study 6627821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 28351446 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal supplementation with fish oil and/or 5-methyltetrahydrofolate
Number of subjects: 74
Study 28351446 — intervention group
Group type: EXPERIMENTAL
Intervention: Head circumference at 4 years
Number of subjects: 74
Study 28523223 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS during extinction consolidation
Number of subjects: 28
Study 28523223 — intervention group
Group type: COMPARATOR
Intervention: tDCS during extinction learning
Number of subjects: 28
Study 27129759 — intervention group
Group type: EXPERIMENTAL
Intervention: Showering at 2 days postoperatively
Number of subjects: 32
Study 27129759 — intervention group
Group type: COMPARATOR
Intervention: Showering at 2 weeks postoperatively
Number of subjects: 32
Study 24418365 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) for 18 months without bisphosphonates
Number of subjects: 123
Study 24418365 — intervention group
Group type: COMPARATOR
Intervention: Shorter androgen deprivation therapy (ADT) course combined with bisphosphonates
Number of subjects: 123
Study 24418365 — intervention group
Group type: COMPARATOR
Intervention: Prostate cancer patients with only nodal metastases or BF
Number of subjects: 123
Study 24418365 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not experience biochemical failure (BF)
Number of subjects: 123
Study 23078756 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted treatment
Number of subjects: 0
Study 23078756 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy
Number of subjects: 0
Study 23078756 — intervention group
Group type: COMPARATOR
Intervention: Patients who lost drug free remission
Number of subjects: 0
Study 19324974 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 30
Study 19324974 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 30
Study 19324974 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg or 80 mg)
Number of subjects: 30
Study 19324974 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 30
Study 19324974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17562956 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation of large areas around both ipsilateral pulmonary veins (group II)
Number of subjects: 110
Study 17562956 — intervention group
Group type: COMPARATOR
Intervention: Isolation of each individual pulmonary vein (group I)
Number of subjects: 110
Study 12853502 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled triamcinolone, 1,200 microg daily
Number of subjects: 221
Study 12853502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 10214011 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia (Group A and C)
Number of subjects: 135
Study 10214011 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (Group B and D)
Number of subjects: 135
Study 8538705 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-component acellular DTP vaccine (2566 children)
Number of subjects: 9829
Study 8538705 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-component acellular DTP vaccine (2587 children)
Number of subjects: 9829
Study 8538705 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell DTP vaccine (2102 children)
Number of subjects: 9829
Study 8538705 — intervention group
Group type: COMPARATOR
Intervention: Control group (DT vaccine, 2574 children)
Number of subjects: 9829
Study 8538705 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell vaccine
Number of subjects: 9829
Study 2070378 — intervention group
Group type: EXPERIMENTAL
Intervention: NH4F treatment
Number of subjects: 58
Study 2070378 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF treatment
Number of subjects: 58
Study 2070378 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 58
Study 7055433 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 hours of penicillin G potassium and doxycycline hyclate
Number of subjects: 82
Study 7055433 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of penicillin G potassium and doxycycline hyclate
Number of subjects: 82
Study 7055433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intestinal penetration)
Number of subjects: 82
Study 7055433 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 hours and 5 days of antibiotics
Number of subjects: 82
Study 7055433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal penetration
Number of subjects: 82
Study 31782032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent chemotherapy (two times four cycles)
Number of subjects: 398
Study 31782032 — intervention group
Group type: COMPARATOR
Intervention: Continuous chemotherapy (eight subsequent cycles)
Number of subjects: 398
Study 31003136 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test for Groups (TSST-G)
Number of subjects: 70
Study 31003136 — intervention group
Group type: COMPARATOR
Intervention: Non-stressful control condition
Number of subjects: 70
Study 28860402 — intervention group
Group type: EXPERIMENTAL
Intervention: Targon PFT nail
Number of subjects: 400
Study 28860402 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw (SHS)
Number of subjects: 400
Study 25985446 — intervention group
Group type: EXPERIMENTAL
Intervention: AI/2-CDA (6 mg/m²/d, days 1, 3) in combination with cytarabine/idarubicin (AI=500 mg/m² cytarabine 5 days continuous infusion plus 7 mg/m²/d idarubicin, days 3 and 5)
Number of subjects: 343
Study 25985446 — intervention group
Group type: COMPARATOR
Intervention: AI (500 mg/m² cytarabine 5 days continuous infusion plus 7 mg/m²/d idarubicin, days 3 and 5)
Number of subjects: 343
Study 23303767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (12 weeks of exercise training and 1 year of psycho-educational follow-up)
Number of subjects: 196
Study 23303767 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study 23303767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 196
Study 23303767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 196
Study 21735660 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated therapy of traditional Chinese and Western medicine
Number of subjects: 52
Study 21735660 — intervention group
Group type: COMPARATOR
Intervention: Control group (transurethral plasmakentic vaporization, anti-infection, rehydration, and supportive therapies)
Number of subjects: 52
Study 19906345 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d memantine
Number of subjects: 21
Study 19906345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17012721 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Scotchbond Multipurpose Dental Adhesive (SBMP)
Number of subjects: 10
Study 17012721 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CFSE)
Number of subjects: 10
Study 17012721 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT (PBNT)
Number of subjects: 10
Study 17012721 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ1
Number of subjects: 10
Study 16244759 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid intervention
Number of subjects: 380
Study 10507241 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine formulation 1
Number of subjects: 0
Study 10507241 — intervention group
Group type: COMPARATOR
Intervention: Amoxapine formulation 2
Number of subjects: 0
Study 10507241 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hydroxyamoxapine
Number of subjects: 0
Study 10507241 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-hydroxyamoxapine
Number of subjects: 0
Study 8735578 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 8
Study 8735578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1755739 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA34 1 microgram
Number of subjects: 2
Study 1755739 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA34 3 micrograms
Number of subjects: 2
Study 1755739 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA34 10 micrograms
Number of subjects: 2
Study 1755739 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA34 10 micrograms once daily for 7 days
Number of subjects: 2
Study 6124474 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 78
Study 6124474 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 78
Study 6124474 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (after crossover)
Number of subjects: 78
Study 6124474 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (after crossover)
Number of subjects: 78
Study 31577070 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis plus platelet-rich plasma (PRP)
Number of subjects: 30
Study 31577070 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis plus hyaluronic acid (HA)
Number of subjects: 30
Study 31577070 — intervention group
Group type: COMPARATOR
Intervention: Arthrocentesis only (control)
Number of subjects: 30
Study 29637837 — intervention group
Group type: EXPERIMENTAL
Intervention: Aligned teeth
Number of subjects: 90
Study 29637837 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary stainless steel labial fixed appliance
Number of subjects: 90
Study 29637837 — intervention group
Group type: EXPERIMENTAL
Intervention: Absent maxillary left lateral incisor
Number of subjects: 90
Study 29637837 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 90
Study 27106176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilisate formulation
Number of subjects: 47
Study 27106176 — intervention group
Group type: COMPARATOR
Intervention: Tablet formulation
Number of subjects: 47
Study 27106176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 47
Study 27106176 — intervention group
Group type: COMPARATOR
Intervention: Fed state
Number of subjects: 47
Study 24698570 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 fractional laser plus radiofrequency
Number of subjects: 10
Study 24698570 — intervention group
Group type: COMPARATOR
Intervention: CO2 fractional laser
Number of subjects: 10
Study 23146788 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed type 1 diabetes (DMT1) patients immediately after treatment of diabetic ketoacidosis (study I)
Number of subjects: 140
Study 23146788 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without symptoms suggestive of urolithiasis)
Number of subjects: 140
Study 19747796 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgust conditioning and extinction procedure
Number of subjects: 0
Study 19747796 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgust sensitivity
Number of subjects: 0
Study 19747796 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy of the disgusting US during extinction
Number of subjects: 0
Study 17918321 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiotropic therapy (nitrates, beta-blockers, ACE inhibitors on demand, diuretics, antioxidants) and placebo
Number of subjects: 58
Study 17918321 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cardiotropic therapy plus impase (1 tablet every other day for 3 months)
Number of subjects: 58
Study 16159592 — intervention group
Group type: EXPERIMENTAL
Intervention: CBTgsh
Number of subjects: 90
Study 16159592 — intervention group
Group type: EXPERIMENTAL
Intervention: BWLgsh
Number of subjects: 90
Study 16159592 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 90